Autumn McRee, Vice President, GI Malignancies DAS Leader at The Johnson & Johnson Innovative Medicine, shared on LinkedIn:
“This week as the oncology community recognized World Pancreatic Cancer Day, I remembered my why – the many patients I treated with this aggressive disease during my time in clinical practice. My why includes Mary, a patient who was my age when she was diagnosed and impressed upon me the undeniable urgency to find better treatments for pancreatic cancer.
Mary passed away in 2022 but her life and legacy continue to fuel my momentum to build the most novel and innovative portfolio for GI cancers at Johnson & Johnson Innovative Medicine. Progress has been made but it’s just the beginning.”
You can also read:
World Pancreatic Cancer Day 2026: From Silent Symptoms to the Urgent Need for Earlier Diagnosis
